Novel Polymorphs Of Ribociclib Succinate

Mylan Laboratories Ltd
Granted App No 201941018391 Patent 477568 Chemical

Patent information

IP India · live record
Application number
201941018391
Filing date
08 May 2019
Status
Granted
Legal status
Inforce
Publication number
46/2020
Publication type
INA
Invention field
Chemical
Patent number
477568
Grant date
06 December 2023
Next renewal due
08 May 2026Overdue

Abstract

The present invention relates to novel crystalline forms of Ribociclib Succinate and its preparation process.

Applicants

1
India
Mylan Laboratories Ltd Mylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad – 500033, India

Inventors

6
India
Ramakoteswara Rao JettiMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India
India
Daveedu BhatrajuMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India
India
Rama Mohana Rao GoliviMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India
India
Manukonda Seshadri RaoMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India
India
Sureshbabu JayachandraMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India
India
Chandra has KhanduriMylan Laboratories Ltd, Plot No 564/A/22, Road No 92, Jubilee Hills, Hyderabad 500033 India

Claims

13
1 Crystalline Ribociclib Succinate Form M11 characterized by powder X-ray diffraction pattern having peaks at 4.5, 4.9, 6.3, 7.0, 7.6, 9.1, 9.8, 10.3, 10.8, 11.2, 12.4, 13.1, 13.4, 14.0, 15.0, 15.9, 16.8, 17.8, 18.1, 19.4, 19.9, 20.6, 21.1, 21.7, 22.6, 23.9, 25.3, 25.9, 26.7, 28.9, 30.8, 31.8, .32.9 34.8 and 36.0 ±0.2° degrees 2?. 2: The crystalline Ribociclib Succinate Form M11 as claimed in claim 1, is prepared comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M11 of Ribociclib Succinate.
3 The process as claimed in claim 2, wherein the organic solvent is selected from Isobutanol, 2-methyl-2-butanol and 3-methyl-1-butanol or methyl ethyl ketone.
4 The process as claimed in claim 2, wherein the reaction mixiture is heated to 50-75°C and cooled to 20-25°C
5 Crystalline Ribociclib Succinate Form M12 characterized by powder X-ray diffraction pattern having peaks at 4.52, 6.96, 14.90, 15.86, 19.30, 19.91, 21.64, 22.58, 23.77 and 24.99 ±0.2° degrees 2?
6 The crystalline Ribociclib Succinate Form M12 as claimed in claim 5, is prepared comprising the steps of: a) suspending Ribociclib and succinic acid in 2-methyl-2-butanol. b) heating and cooling the reaction mixture c) isolating crystalline Form M12 of Ribociclib Succinate. 16
7 Crystalline Ribociclib Succinate Form M10 characterized by powder X-ray diffraction pattern having peaks at 5.9, 8.5, 11.4, 11.9, 13.5, 15.8, 16.8, 17.5, 18.3, 19.6, 21.1, 22.3, 25.7, 27.0 and 28.5 ±0.2° degrees 2?.
8 The crystalline Ribociclib Succinate Form M10 as claimed in claim 7, is prepared comprising the steps of: a) suspending Ribociclib in tertiary amyl alcohol b) adding succinic acid c) heating and cooling the reaction mixture d) isolating crystalline Form M10 of Ribociclib Succinate.
9 Crystalline Ribociclib Succinate Form M14 characterized by powder X-ray diffraction pattern having peaks at 4.73, 7.77, 9.35, 10.49, 12.20, 14.10, 17.78, 18.95, 19.33, 19.64, 20.43, 21.16 21.94 ±0.2° degrees 2?.
10 The crystalline Ribociclib Succinate Form M14 as claimed in claim 9, is prepared comprising the steps of: d) dissolving Ribociclib in 1,4 Dioxane e) adding solution of step a to a solution of succinic acid in isopropyl alcohol f) isolating crystalline Form M14 of Ribociclib Succinate.
11 Crystalline Ribociclib Succinate Form M15 characterized by powder X-ray diffraction pattern having peaks at 6.93, 9.84, 10.22, 14.35, 16.71, 18.90, 19.52, 19.77, 20.31, 20.57 ±0.2° degrees 2?.
12 The crystalline Ribociclib Succinate Form M15 as claimed in claim 11, is prepared comprising the steps of: d) suspending Ribociclib Succinate form M14 in n-Heptane e) heating and cooling the reaction mixture f) isolating crystalline Form M15 of Ribociclib Succinate. 17
13 The process as claimed in claim 12, wherein the reaction mixiture is heated to 75- 85°C and cooled to 20-35°C and the isolation of Form M15 is carried by filteration followed by suck drying under nitrogen or drying the material under vacuum.
14 A pharmaceutical composition comprising crystalline Ribociclib Succinate selected from M10, M11, M12, M14 or M15 and a pharmaceutically acceptable excipient.

Specification

Show full textCollapse

DESC:CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of the earlier filing date of Indian provisional patent application no IN 201941018391 filed on May 08, 2019. FIELD OF THE INVENTION: The present invention relates to novel crystalline forms of Ribociclib Succinate and its preparation process. BACKGROUND OF THE INVENTION: Ribociclib Succinate, chemically known as Butanedioic acid—7-cyclopentyl-N,N dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1/1) and represented by Formula-I is approved for the inhibitor of cyclin D1/CDK4 and CDK6. It is similar to Palbociclib both structurally and pharmacologically, acting as a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Formula I Ribociclib and it’s pharmaceutically acceptable salts thereof was first claimed in US 8415355B2 patent. This patent also disclosed a process for the preparation of ribociclib. US 9193732B2 disclosed the polymorphic forms of succinate salt of ribociclib, characterized by XRD, DSC, TGA, post-DVS XRD, post-DVS DSC and post-DVS TGA figures and non-hydrate form, hydrate form and mixtures. 3 US 20170342075 disclosed crystalline form I of mono-succinate salt of ribociclib, characterized by XRD peaks. This application also disclosed Hemi-succinate Form A, adipate salt Form A, Maleate salt Form A and Glycolic acid salt Form A. EP application EP 3156406A1 claimed crystalline forms of ribociclib free base and amorphous form. PCT application WO 2018051280 disclosed different salts, amorphous form of ribociclib and amorphous solid dispersion of ribociclib. IN application IN 201741000072 claimed crystalline forms of ribociclib Succinate DR1, DR2, DR3, DR4, DR5, DR6, DR7 & DR8. The inventors of the present invention have developed novel crystalline forms of Ribociclib Succinate which are suitable for formulation development. OBJECT AND SUMMARY OF THE INVENTION: The main object of the present invention is to provide novel crystalline forms of Ribociclib Succinate. In one aspect, the present invention is to provide a novel crystalline form of Ribociclib Succinate designated as Form M10. In yet another aspect, the Ribociclib Succinate crystalline form M10 is characterized by powder X-ray diffraction pattern having peaks at 5.9, 8.5, 11.4, 11.9, 12.2, 13.5, 14.1, 15.3, 15.8, 16.8, 17.5, 18.3, 19.0, 19.6, 20.4, 21.1, 21.6, 22.3, 23.3, 25.7, 27.0, 27.7, 28.5, 29.3, 30.4, 31.1, 32.4, 34.4, 35.2, 37.4, 40.9 and 42.9 ±0.2° degrees 2?. In yet another aspect, the crystalline Form M10 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 1. 4 In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M10 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib in tertiary amyl alcohol b) adding succinic acid c) heating and cooling the reaction mixture d) isolating crystalline Form M10 of Ribociclib Succinate. In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M11. In yet another aspect, the the Ribociclib Succinate crystalline form M11 is characterized by powder X-ray diffraction pattern having peaks at 4.5, 4.9, 6.3, 7.0, 7.6, 9.1, 9.8, 10.3, 10.8, 11.2, 12.4, 13.1, 13.4, 14.0, 15.0, 15.9, 16.8, 17.8, 18.1, 19.4, 19.9, 20.6, 21.1, 21.7, 22.6, 23.9, 25.3, 25.9, 26.7, 28.9, 30.8, 31.8, .32.9 34.8 and 36.0 ±0.2° degrees 2?. In yet another aspect, the crystalline Form M11 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 2. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M11 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M11 of Ribociclib Succinate. In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M12. In yet another aspect, the Ribociclib Succinate crystalline form M12 is characterized by powder X-ray diffraction pattern having peaks at 4.52, 6.96, 14.90, 15.86, 19.30, 19.91, 21.64, 22.58, 23.77 and 24.99 ±0.2° degrees 2?. 5 In yet another aspect, the crystalline Form M12 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 3. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M12 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M12 of Ribociclib Succinate. In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M14. In yet another aspect, the Ribociclib Succinate crystalline Form M14 is characterized by powder X-ray diffraction pattern having peaks at 4.73, 7.77, 9.35, 10.49, 12.20, 14.10, 17.78, 18.95, 19.33, 19.64, 20.43, 21.16 21.94 ±0.2° degrees 2?. In yet another aspect, the crystalline Form M14 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 4. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M14 of Ribociclib Succinate comprising the steps of: a) dissolving Ribociclib in 1,4- Dioxane b) adding solution of step a to a solution of succinic acid in isopropyl alcohol c) isolating crystalline Form M14 of Ribociclib Succinate. In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M15. In yet another aspect, the Ribociclib Succinate crystalline Form M15 is characterized by powder X-ray diffraction pattern having peaks at 6.93, 9.84, 10.22, 14.35, 16.71, 18.90, 19.52, 19.77, 20.31, 20.57 ±0.2° degrees 2?. 6 In yet another aspect, the crystalline Form M15 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 5. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M15 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib Succinate Form M14 in n-Heptane b) heating and cooling the reaction mixture c) isolating crystalline Form M15 of Ribociclib Succinate. Brief description of the figures: Figure 1: Illustrates the powder X-ray diffraction (PXRD) pattern of Ribociclib Succinate Form M10. Figure 2: Illustrates the powder X-ray diffraction (PXRD) pattern of Ribociclib Succinate Form M11. Figure 3: Illustrates the powder X-ray diffraction (PXRD) pattern of Ribociclib Succinate Form M12. Figure 4: Illustrates the powder X-ray diffraction (PXRD) pattern of Ribociclib Succinate Form M14. Figure 5: Illustrates the powder X-ray diffraction (PXRD) pattern of Ribociclib Succinate Form M15. DETAILED DESCRIPTION: The present invention relates to novel crystalline forms of Ribociclib Succinate. In one embodiment, the present invention relates to novel crystalline form of Ribociclib Succinate designated as Form M10. In yet another embodiment, the Ribociclib Succinate crystalline Form M10 is characterized by powder X-ray diffraction pattern having peaks at 5.9, 8.5, 11.4, 11.9, 7 12.2, 13.5, 14.1, 15.3, 15.8, 16.8, 17.5, 18.3, 19.0, 19.6, 20.4, 21.1, 21.6, 22.3, 23.3, 25.7, 27.0, 27.7, 28.5, 29.3, 30.4, 31.1, 32.4, 34.4, 35.2, 37.4, 40.9 and 42.9 ±0.2° degrees 2?. In yet another embodiment, the crystalline Form M10 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 1. In yet another embodiment, the present invention is to provide a process for the preparation of crystalline Form M10 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib in tertiary amyl alcohol b) adding succinic acid c) heating and cooling the reaction mixture d) isolating crystalline Form M10 of Ribociclib Succinate. According to the present invention, Ribociclib may be suspended in tertiary Amyl alcohol and added Succinic acid. This suspension may be heated at a temperature of about 50-55°C and stirred for 1h followed by cooling to about 25±5°C and stirred for about 15 hours. The resultant solid may be filtered and dried to obtain crystalline Form M10 of Ribociclib Succinate. In yet another embodiment, the present invention relates to novel crystalline form of Ribociclib Succinate designated as Form M11. In yet another embodiment, the Ribociclib Succinate crystalline Form M11 is characterized by powder X-ray diffraction pattern having peaks at 4.5, 4.9, 6.3, 7.0, 7.6, 9.1, 9.8, 10.3, 10.8, 11.2, 12.4, 13.1, 13.4, 14.0, 15.0, 15.9, 16.8, 17.8, 18.1, 19.4, 19.9, 20.6, 21.1, 21.7, 22.6, 23.9, 25.3, 25.9, 26.7, 28.9, 30.8, 31.8, .32.9 34.8 and 36.0 ±0.2° degrees 2?. In yet another embodiment, the crystalline Form M11 of Ribociclib Succinate may be characterized by the powder X-ray diffraction pattern as given in Figure 2. 8 In yet another embodiment, the present invention relates to a process for the preparation of crystalline Form M11 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M11 of Ribociclib Succinate. According to the present invention, Ribociclib and succinic acid may be suspended in an organic solvent selected from alcohols preferably Isobutanol, 2-methyl-2-butanol and 3-methyl-1-butanol or ketone solvents such as methyl ethyl ketone. This suspension may be heated at a temperature of about 50-80°C and stirred. The resultant reaction mass may be cooled to about 25±5°C and stirred for about 15 hours. The reaction mass was filtered and dried to obtain crystalline Form M11 of Ribociclib Succinate. In yet another embodiment, the present invention relates to novel crystalline form of Ribociclib Succinate designated as Form M12. In yet another embodiment, the Ribociclib Succinate crystalline form M12 is characterized by powder X-ray diffraction pattern having peaks at 4.52, 6.96, 14.90, 15.86, 19.30, 19.91, 21.64, 22.58, 23.77 and 24.99 ± 0.2° degrees 2?. In yet another embodiment, the crystalline Form M12 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 3. In yet another embodiment, the present invention relates to a process for the preparation of crystalline Form M12 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M12 of Ribociclib Succinate. 9 According to the present invention, Ribociclib and succinic acid may be suspended in an organic solvent selected from alcohols preferably Isobutanol, 2-methyl-2-butanol or 3-methyl-1-butanol. This suspension may be heated at a temperature of about 50-70°C and stirred. The resultant reaction mass may be cooled to about 25±5°C and stirred for about 2 hours. The reaction mass was filtered and dried to obtain crystalline Form M12 of Ribociclib Succinate. In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M14. In yet another aspect, the Ribociclib Succinate crystalline form M14 is characterized by powder X-ray diffraction pattern having peaks at 4.73, 7.77, 9.35, 10.49, 12.20, 14.10, 17.78, 18.95, 19.33, 19.64, 20.43, 21.16 21.94 ±0.2° degrees 2?. In yet another aspect, the crystalline Form M14 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 4. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M14 of Ribociclib Succinate comprising the steps of: a) dissolving Ribociclib in 1,4- Dioxane b) adding solution of step a to a solution of succinic acid in isopropyl alcohol c) isolating crystalline Form M14 of Ribociclib Succinate. According to the present invention, Ribociclib may be dissolved in 1,4 Dioxane and heated to 70-80°C to obtain clear solution. Seperately, Succinic acid may be taken in isopropyl alcohol and heated to 70-80°C. The clear Ribociclib solution may be added to the succinic acid solution and maintain the reaction mixture at 70-80°C followed by cooling to 25-35°C. The solid may be filtered, suck dried under nitrogen to obtain crystalline Form M14 of Ribociclib Succinate 10 In another aspect, the present invention is to provide novel crystalline form of Ribociclib Succinate designated as Form M15. In yet another aspect, the Ribociclib Succinate crystalline form M15 is characterized by powder X-ray diffraction pattern having peaks at 6.93, 9.84, 10.22, 14.35, 16.71, 18.90, 19.52, 19.77, 20.31, 20.57 ±0.2° degrees 2?. In yet another aspect, the crystalline Form M15 of Ribociclib Succinate has the powder X-ray diffraction pattern as given in Figure 5. In yet another aspect, the present invention is to provide a process for the preparation of crystalline Form M15 of Ribociclib Succinate comprising the steps of: a) suspending Ribociclib Succinate Form M14 in n-Heptane b) heating and cooling the reaction mixture c) isolating crystalline Form M15 of Ribociclib Succinate. According to the present invention, crystalline Form M14 of Ribociclib Succinate may be suspended in n-Heptane and heated the reaction mixture to 75-85°C. The reaction may be cooled to 25-35°C and the solid obtained may be filtered, suck dried under nitrogen or dried under vacuum to obtain crystalline Form M15 of Ribociclib Succinate In yet another embodiment, the present invention relates to pharmaceutical composition comprising either of the crystalline Ribociclib Succinate Forms M10, M11, M12, M14 or M15 and pharmaceutically acceptable excipients. Indicative stability: In yet another embodiment, the physical and chemical stability of Ribociclib Succinate Form M10 was determined by storing the samples at 5±3°C and 25°C/60% relative humidity (RH) conditions for six months. The samples were analyzed by PXRD and purity by HPLC. The results are shown in Table 1. The Ribociclib Succinate Form M10 11 was found to be physically and chemically stable at 5±3°C and 25°C/60% relative humidity (RH) conditions up to six months. In yet another embodiment, the physical and chemical stability of Ribociclib Succinate Form M11 was determined by storing the samples at 40°C/75% relative humidity (RH) and at 25°C/60% relative humidity (RH) conditions for six months. The samples were analyzed by PXRD and purity by HPLC. The results are shown in Table 2. The Ribociclib Succinate Form M11 was found to be physically and chemically stable at 40°C/75% relative humidity (RH) and at 25°C/60% relative humidity (RH) conditions up to six months. Table 1 Conditions/ Polymorph Ribociclib Succinate Form M10 PXRD HPLC purity at 5±3°C Initial Crystalline form 99.5 1 months Stable 99.5 3 months Stable 99.6 6 months Stable 99.6 at 25°C/60% RH Initial Crystalline form 99.5 1 months Stable 99.5 3 months Stable 99.5 6 months Stable 99.4 Table 2 Conditions/ Polymorph Ribociclib Succinate Form M11 PXRD HPLC purity at 40°C/75% RH 12 Initial Crystalline form 99.4 1 months Stable 99.4 3 months Stable 99.5 6 months Stable 99.4 at 25°C/60% RH Initial Crystalline form 99.4 1 months Stable 99.5 3 months Stable 99.6 6 months Stable 99.5 The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention in anyway. EXAMPLES: Example 1: Ribociclib Succinate Form M10. Charged Ribociclib (5g) and tertiary Amyl alcohol (100mL) into the RBF. The suspension was stirred for 10 min and charged succinic acid (1.43g) into RBF at 25±5°C. The suspension was heated to 50±5°C and stirred for 1h at 50±5°C. The suspension was cooled to 25±5°C and stirred for 15 h at 25±5°C. The reaction mass was filtered, suckdried at 25-30°C for 30minutes and further dried the material under vacuum at 30°C 24 h. The solid obtained was identified as crystalline Form M10 of Ribociclib Succinate. Yield=5.8g Example 2: Ribociclib Succinate Form M11. Charged Ribociclib (4g), succinic acid (1.14g) and Isobutanol (80 mL) into the RBF at 25±5°C. The suspension was heated to 50-55°C and stirred for 1h at 50-55°C. The suspension was cooled to 25±5°C and stirred for 15 h at 25±5°C. The reaction mass was filtered and washed with Isobutanol (8mL), suck-dried at 25-30°C for 30minutes and further dried the material under vacuum at 30°C for 16 h. The solid obtained was identified as crystalline Form M11 of Ribociclib Succinate. Yield=4.9g 13 Example 3: Ribociclib Succinate Form M11 Charged Ribociclib (2.5g), succinic acid (760mg) and 2-methyl-2-butanol (50 mL) into the RBF at 25±5°C. The suspension was heated to 50-55°C and stirred for 20h at 50- 55°C. The reaction mass was filtered, suck-dried at 25-30°C for 30minutes and further dried the material under vacuum at 50-55°C for 15 h. The solid obtained was identified as crystalline Form M11 of Ribociclib Succinate. Yield=2.6g Example 4: Ribociclib Succinate Form M11 Charged Ribociclib (0.5g), succinic acid (140mg) and 3-methyl-1-butanol (10 mL) into the RBF at 25±5°C. The suspension was heated to 70-75°C and stirred for 1h at 70-75°C. The suspension was cooled to 25±5°C and stirred for 15 h at 25±5°C. The reaction mass was filtered and suck dried for 30 min. The solid obtained was identified as crystalline Form M11 of Ribociclib Succinate. Example 5: Ribociclib Succinate Form M11 In a RBF, Charge Ribociclib (2g), Methyl ethyl ketone (40mL) and Succinic acid (0.6g) at 25±5°C. Heated the suspension to 75±5°C and stir for 1h at 75±5°C. The suspension was cooled to 25±5°C and stirred for 16h at 25±5°C. The reaction mass was filtered and dried under vacuum at 40°C for 16 h. The solid obtained was identified as crystalline Form M11 of Ribociclib Succinate. Yield=2.3 g Example 6: Ribociclib Succinate Form M12 Charged Ribociclib (0.5g), succinic acid (140mg) and 2-methyl-2-butanol (15 mL) into the RBF at 25±5°C. The suspension was heated to 60-65°C and stirred for 1h at 60-65°C. The suspension was cooled to 25±5°C and stirred for 1h at 25±5°C. The reaction mass was filtered and suck dried for 30 min. The solid obtained was identified as crystalline Form M12 of Ribociclib Succinate. 14 Example ,CLAIMS:1. Crystalline Ribociclib Succinate Form M11 characterized by powder X-ray diffraction pattern having peaks at 4.5, 4.9, 6.3, 7.0, 7.6, 9.1, 9.8, 10.3, 10.8, 11.2, 12.4, 13.1, 13.4, 14.0, 15.0, 15.9, 16.8, 17.8, 18.1, 19.4, 19.9, 20.6, 21.1, 21.7, 22.6, 23.9, 25.3, 25.9, 26.7, 28.9, 30.8, 31.8, .32.9 34.8 and 36.0 ±0.2° degrees 2?. 2: The crystalline Ribociclib Succinate Form M11 as claimed in claim 1, is prepared comprising the steps of: a) suspending Ribociclib and succinic acid in an organic solvent. b) heating and cooling the reaction mixture c) isolating crystalline Form M11 of Ribociclib Succinate. 3. The process as claimed in claim 2, wherein the organic solvent is selected from Isobutanol, 2-methyl-2-butanol and 3-methyl-1-butanol or methyl ethyl ketone. 4. The process as claimed in claim 2, wherein the reaction mixiture is heated to 50-75°C and cooled to 20-25°C 5. Crystalline Ribociclib Succinate Form M12 characterized by powder X-ray diffraction pattern having peaks at 4.52, 6.96, 14.90, 15.86, 19.30, 19.91, 21.64, 22.58, 23.77 and 24.99 ±0.2° degrees 2? 6. The crystalline Ribociclib Succinate Form M12 as claimed in claim 5, is prepared comprising the steps of: a) suspending Ribociclib and succinic acid in 2-methyl-2-butanol. b) heating and cooling the reaction mixture c) isolating crystalline Form M12 of Ribociclib Succinate. 16 7. Crystalline Ribociclib Succinate Form M10 characterized by powder X-ray diffraction pattern having peaks at 5.9, 8.5, 11.4, 11.9, 13.5, 15.8, 16.8, 17.5, 18.3, 19.6, 21.1, 22.3, 25.7, 27.0 and 28.5 ±0.2° degrees 2?. 8. The crystalline Ribociclib Succinate Form M10 as claimed in claim 7, is prepared comprising the steps of: a) suspending Ribociclib in tertiary amyl alcohol b) adding succinic acid c) heating and cooling the reaction mixture d) isolating crystalline Form M10 of Ribociclib Succinate. 9. Crystalline Ribociclib Succinate Form M14 characterized by powder X-ray diffraction pattern having peaks at 4.73, 7.77, 9.35, 10.49, 12.20, 14.10, 17.78, 18.95, 19.33, 19.64, 20.43, 21.16 21.94 ±0.2° degrees 2?. 10. The crystalline Ribociclib Succinate Form M14 as claimed in claim 9, is prepared comprising the steps of: d) dissolving Ribociclib in 1,4 Dioxane e) adding solution of step a to a solution of succinic acid in isopropyl alcohol f) isolating crystalline Form M14 of Ribociclib Succinate. 11. Crystalline Ribociclib Succinate Form M15 characterized by powder X-ray diffraction pattern having peaks at 6.93, 9.84, 10.22, 14.35, 16.71, 18.90, 19.52, 19.77, 20.31, 20.57 ±0.2° degrees 2?. 12. The crystalline Ribociclib Succinate Form M15 as claimed in claim 11, is prepared comprising the steps of: d) suspending Ribociclib Succinate form M14 in n-Heptane e) heating and cooling the reaction mixture f) isolating crystalline Form M15 of Ribociclib Succinate. 17 13. The process as claimed in claim 12, wherein the reaction mixiture is heated to 75- 85°C and cooled to 20-35°C and the isolation of Form M15 is carried by filteration followed by suck drying under nitrogen or drying the material under vacuum. 14. A pharmaceutical composition comprising crystalline Ribociclib Succinate selected from M10, M11, M12, M14 or M15 and a pharmaceutically acceptable excipient.

Documents

Sign in to open
Application documents
1 201941018391-PROVISIONAL SPECIFICATION [08-05-2019(online)].pdf 08 May 2019
2 201941018391-FORM 1 [08-05-2019(online)].pdf 08 May 2019
3 201941018391-DRAWINGS [08-05-2019(online)].pdf 08 May 2019
4 201941018391-Proof of Right (MANDATORY) [27-08-2019(online)].pdf 27 Aug 2019
5 201941018391-Request Letter-Correspondence [03-03-2020(online)].pdf 03 Mar 2020
6 201941018391-DRAWING [07-05-2020(online)].pdf 07 May 2020
7 201941018391-COMPLETE SPECIFICATION [07-05-2020(online)].pdf 07 May 2020
8 201941018391-FORM 3 [22-12-2020(online)].pdf 22 Dec 2020
9 201941018391-FORM 18 [29-07-2022(online)].pdf 29 Jul 2022
10 201941018391-FER.pdf 03 Aug 2022
11 201941018391-FER_SER_REPLY [27-01-2023(online)].pdf 27 Jan 2023
12 201941018391-PatentCertificate06-12-2023.pdf 06 Dec 2023
13 201941018391-IntimationOfGrant06-12-2023.pdf 06 Dec 2023
14 201941018391-POWER OF AUTHORITY [26-04-2025(online)].pdf 26 Apr 2025
15 201941018391-FORM-16 [26-04-2025(online)].pdf 26 Apr 2025
16 201941018391-ASSIGNMENT WITH VERIFIED COPY [26-04-2025(online)].pdf 26 Apr 2025
17 201941018391-Response to office action [09-07-2025(online)].pdf 09 Jul 2025
Search strategy
1201941018391SEARCHE_03-08-2022.pdf

ERegister / renewals

Inforce
3rd Renewed 08 Dec 2023 Period 08 May 2021 – 08 May 2022 · CBR 57171 · Certificate 113228 ₹4,000
4th Renewed 08 Dec 2023 Period 08 May 2022 – 08 May 2023 · CBR 57171 · Certificate 113229 ₹4,000
5th Renewed 08 Dec 2023 Period 08 May 2023 – 08 May 2024 · CBR 57171 · Certificate 113230 ₹4,000
6th Renewed 07 May 2024 Period 08 May 2024 – 08 May 2025 · CBR 30461 · Certificate 90261 ₹4,000
7th Renewed 28 Apr 2025 Period 08 May 2025 – 08 May 2026 · CBR 25301 · Certificate 32619 ₹12,000